Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine

By sjmartinez • November 29, 2022

Edwards GG, Miyashita-Ochoa A, Castillo EG, Goodman-Meza D, Kalofonos I, Landovitz RJ, Leibowitz AA, Pulsipher C, El Sayed E, Shoptaw S, Shover CL, Tabajonda M, Yang YS, Harawa NT. Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS Behav. 2022 Sep 5:1–15. doi: 10.1007/s10461-022-03817-z. Epub ahead of print. PMID: 36063243; PMCID: PMC9443641.

Tags: Addiction medicine, Antiretroviral medication, Cost, HIV treatment, Implementation barriers and facilitators, Infectious Diseases, Long acting injectable medication, Psychiatry, Publications

Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates

Youssef EG, Gebremariam T, Gu Y, Patterson H, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of EL219, a next-generation polyene antifungal, in[...]

Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship

Paras ML, Stead W, Bisono-Garcia B, Pottinger PS, Aziz R, Aziz M, Balba GP, Blackburn BG, Butt S, Chow B, Graber CJ, Muñoz-Gomez S, Pellegrino[...]

Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness

Tewari SE, Hoffman R, Lockman S, Flanagan CF, Webb KA, Horsfall S, Chimwaza A, Dugdale CM, Currier J, Dhodho E, Neilan AM, Masiye K, Rana[...]